According to "National Stroke Association" literature:
"The only drug that has received FDA approval for acute ischemic stroke treatment is a recombinant form of t-PA (tissue plasminogen activator). Its approval in June 1996 sparked increased public and medical interest in stroke. T-PA must be administered 90-180 minutes after the onset of stroke. However, recent studies have found that 42 percent of stroke patients wait as long as 24 hours before presenting, with 13 hours as the average."
According to a recent press release from NINDS:
"A five-year clinical trial has shown that treatment with the clot-dissolving drug t-PA is an effective emergency treatment for acute ischemic stroke despite some risk from bleeding. The trial found that carefully selected stroke patients who received t-PA treatment within 3 hours of their initial stroke symptoms were at least 30 percent more likely than untreated patients to recover from their stroke with little or no disability after three months. The nationwide study of more than 600 stroke patients was organized and funded by the National Institute of Neurological Disorders and Stroke (NINDS). Results appear in the December 14, 1995, issue of The New England Journal of Medicine.
"Stroke, which leaves millions of adults disabled, is one of the most devastating and costly health problems that we face," said Zach W. Hall, Ph.D., director of the NINDS. "The positive result of this trial should be encouraging to all Americans at risk of stroke who hope to live to a healthy, independent old age. A notable feature of this study is that its quality sets a very high standard for future clinical trials."
It should be noted that although our treatment is most effective when administered within a few days of the onset of stroke, it remains highly effective even if administered months or years after the onset of stroke. There are over 4 million persons currently suffering from stroke related paralysis in the USA alone and approximately 15 million such sufferers in the G-7 countries. It should be further noted that the results of our treatment which claims close to a 100% success rate when administered immediately (as was required in the t-PA trials), are markedly superior to the t-PA trials which resulted in only a 30% improvement over the placebo group. For comparison, it should be noted that placebo groups generally exhibit spontaneous recovery of 10% – 15% of the sample population. The 30% increase that is afforded through the use of t-PA elevates the recovery to about 20% of the population as compared with approximately 99% recovery using our treatment under similar circumstances of immediate treatment, and over 90% overall when treatment is not necessarily provided immediately.
The National Stroke Association also noted that:
" … given the multi-dimensional nature of ischemic brain cell injury, stroke experts predict that no single drug will be able to completely protect the brain during stroke; more likely, a combination of agents will be necessary for full recovery potential."
Complimentary to this statement, our treatment is a holistic combination of several medicines already in use for alternate ailments.
STEM-CELL IMPLANTION RESEARCH
Stem-cell research is a controversial area of science that offers potential for treating diseases ranging from stroke and Alzheimer’s to cancer. Stem cells have the potential of differentiating into more specialized cells in the body.
ReNeuron, a research company from England which currently leads in stem-cell research, has developed a line of neural stem cells for lab rats derived from embryonic tissue. The company inserts a gene into the cells to make them divide at low temperatures. But when the cells are inserted into the brain and reach normal body temperature, the gene switches off and the cells stop dividing and differentiate into brain cells. The inserted stem cells will be specific for stroke.
Although ReNeuron has demonstrated some limited success in lab rats, they have yet to attempt the treatment in on human on a large scale. In contrast, Paralysis Sciences has demonstrated successful full-scale human treatments since 1997 with over 289 documented cases and a near-perfect success rate with no side effects.
COMPARATIVE EUROPEAN STROKE RECOVERY STATISTICS
(Statistics Taken From: Phys Med Rehabil Clin N Am 1999 Nov;10(4):887-906)
The following data is taken from a recent study published by one of Europe’s leading stroke and paralysis rehabilitation centers. It represents the results of their latest techniques and is believed to be highly representative of the state of the art in modern western competitive paralysis treatments. The purpose of this section is to contrast the effectiveness of state-of-the-art conventional paralysis treatment with our treatment.
1. General Distribution of Severity Levels of Stroke Patients treated at the center:
Very Severe 19%
From this data we note that the majority of stroke induced paralysis patients treated exhibited mild paralysis and a minority exhibited very severe paralysis. In contrast, the overwhelming majority of patients treated in our clinic exhibited very severe paralysis.
2. Neurological Impairment Levels in Survivors After Treatment & Rehabilitation at the center:
Impairment After Treatment
Severe or Very Severe 11%
Total Recovery 31%
From this data we note that although the majority of patients treated (67%) were only mildly or moderately paralyzed, the majority of patients failed to recover.
Percentages of Survivors Who Finally Achieved Independent Function at the center:
Initial Severity Level
Very Severe 4%
From this data we again note that only 17% of severely or very severely paralyzed patients regained independent functioning as compared with 98% of severely or very severely paralyzed patients regaining independent functioning with our treatment.